Funding for this research was provided by:
Medical Research Council (MR/J014257/1, CSUB19166, G116/143, MR/M003108/1, G0900421, MR/J01107X/1)
UCLH Biomedical Research Centre
Alzheimer’s Research UK (ARUK-Network 2012-6-ICE, ARUK-PG2014-1946)
Engineering and Physical Sciences Research Council (EP/M02533/1, EP/L016478/1, EP/H046410/1, EP/J020990/1, EP/K005278, EP/J020990/1)
Received: 10 June 2020
Accepted: 4 September 2020
First Online: 17 September 2020
Ethics approval and consent to participate
: The study was approved by the Queen Square Research Ethics Committee (reference number 11/LO/0753) and all participants provided written informed consent.
: Not applicable
: PSJW, TP, JMN, NT, IJAS, ML, MM, NSR, YL and MNR report no disclosures. JMS has received research funding from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals and Eli Lilly and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. SO has received personal compensation for activities and research support from IXICO Ltd. He also received financial support for his research from Siemens Molecular Imaging, MIRADA Medical Solution and GE Healthcare. NCF reports research support from Avid/Lilly, Biogen, Elan/Janssen, GE and Roche and has served on a data safety monitoring committee for Biogen.